At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 392 enrolled
Drug / intervention
TD-9855 Group 1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of TD-9855 in Patients With Fibromyalgia (FM)
In Brief
A Phase 2 clinical trial evaluating TD-9855 Group 1, TD-9855 Group 2, and 1 other intervention for Fibromyalgia. Completed, enrolled 392 participants across 34 sites.
Detailed Summary
The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartNov 2012
Primary CompletionJan 2014
Study CompletionApr 2014
TodayJul 2026
First PostedSep 26, 2012
Enrollment StartNov 1, 2012
Primary CompletionJan 1, 2014
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.8 years ago
Interventions
TD-9855 Group 1drug
TD-9855 Group 2drug
Placebodrug